Call me crazy, but I'm playing the common, and options Nick. I just cannot even imagine the FDA completely closing the door on this drug; it doesn't make sense, so therefore the upside is practically unlimited, and the downside is minimal, in my view.
So I sat there like a dope a week or two ago, when SRPT was knocked down by the panel, and traded under $7 in pre-market. I was going to pull the trigger, and of course I didn't. So now I'm in, in the $17's until approval. The enormously positive sentiment, bullish news releases, and the daily chart showing signs of some serious accumulation tell me after what, 5 years, Sarepta is finally going to get approved. Even a conditional approval will send this stock into the $30's. Good luck to all.
Because this was a fabulous report on every metric. Considering all the customers they added, their branding and leverage, license revenue will grow in the future. I already bought in AH in the $45's, so we'll see.
Didn't you receive the memo? Continental Resources discovered a cure for all diseases. How else can you explain this parabolic move over the past several weeks?
AMT has a nice chart, although a bit extended on the weekly, congrats. Are you short OZRK? So far at least, Block appears correct, although as you suggested a lot of this become a self-fulfilling prophecy. Having said that, it certainly looks like OZRK could eventually head to about $30, before possibly finding support.
Carson Block's Muddy Waters made his living shorting Chinese stocks, most of which had accounting issues or were overvalued for other reasons. He must have a really strong conviction about his position in Ozarks. I did some research, he has a track record of success.
"With Sanofi bidding on MDVN, it's unclear what other companies may pursue RLYP" lol....... so they're downgrading the stock. Sounds like they were supposed to get investment banking business but were turned away. None of this makes any sense to me.
I fully expect Liana Moussatos to reiterate her buy and $47 PPS target tomorrow or Thurday (after the CC)...Was it $47, or $57? I can't recall.
the overhang on the stock was the financing, not whether or not they'll be a buyout. A buyout would just be icing on the cake. How quickly traders forget that when the IBB and most of the biotechs crashed, the narrative was built that because of market conditions, RLYP would not be able to go the banks or the capital markets. Now that overhang is gone. So the only bank in play now is my bank, where I intend to transfer more money to my brokerage account to buy as many shares as I can in the $14's or $15's.
Go have a glass of wine and some dinner....We're good...This deal is very positive. I can't sit here for now and sift through at last count 18 posts by rumrunner and other shorts. I'll catch up with you guys later and tomorrow.
I think the higher interest rate is to allow for the interest only provision in the deal. And as I said earlier, you can't ask for a better outcome, in terms of removing the financing overhang.
To get an interest only provision built into the deal, this explains the higher interest rate. This is exactly what everyone wanted. It's both non-dilutive and buys them time to continue to ramp up scripts while courting suitors. This is clearly a great move.
I would not be surprised at all. As another suggested here a few minutes ago, some of this cash could be to hire an investment bank. But again, a BO is NOT the only strategy for this company. Shorts that don't cover in AH or tomorrow will be very sorry, IMHO.
That's because there is no reason for this drop, other than clowns who think a BO is the only reason for the existence of the stock. As a matter of fact, this removes the financing uncertainty, in that they were able to tap the markets for money.